WallStreetZenWallStreetZen

NASDAQ: TKNO
Alpha Teknova Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for TKNO

Based on 2 analysts offering 12 month price targets for Alpha Teknova Inc

Min Forecast
$7.00-1.13%
Avg Forecast
$7.50+5.93%
Max Forecast
$8.00+12.99%

Should I buy or sell TKNO stock?

Based on 2 analysts offering ratings for Alpha Teknova Inc.

Strong Buy
Strong Buy
2 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model "Buy" agrees with analyst consensus with a "Strong Buy" rating. Learn More

Be the first to know when Wall Street analysts revise their TKNO stock forecasts and price targets.

TKNO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-08-11
lockedlocked$00.00+00.00%2026-08-05

1 of 1

Forecast return on equity

Is TKNO forecast to generate an efficient return?

Company
N/A
Industry
61.82%
Market
168.59%

Forecast return on assets

Is TKNO forecast to generate an efficient return on assets?

Company
N/A
Industry
23.57%

TKNO earnings per share forecast

What is TKNO's earnings per share in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
-$0.31
Avg 2 year Forecast
-$0.27
Avg 3 year Forecast
-$0.20

TKNO revenue forecast

What is TKNO's revenue in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
$46.6M+6.62%
Avg 2 year Forecast
$53.3M+21.94%
Avg 3 year Forecast
$61.9M+41.74%
TKNO's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

TKNO revenue growth forecast

How is TKNO forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
12.06%
Industry
10.5%
Market
13.34%
TKNO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
TKNO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

TKNO vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
TKNO$7.08$7.50+5.93%Strong Buy
CGC$0.98N/AN/A
BIOA$9.52$40.75+328.05%Strong Buy
EBS$6.22$10.00+60.77%Sell
KMDA$8.38N/AN/A
View Top Pharmaceutical Stocks

Alpha Teknova Stock Forecast FAQ

Is Alpha Teknova Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: TKNO) stock is to Strong Buy TKNO stock.

Out of 2 analysts, 2 (100%) are recommending TKNO as a Strong Buy, 0 (0%) are recommending TKNO as a Buy, 0 (0%) are recommending TKNO as a Hold, 0 (0%) are recommending TKNO as a Sell, and 0 (0%) are recommending TKNO as a Strong Sell.

If you're new to stock investing, here's how to buy Alpha Teknova stock.

What is TKNO's earnings growth forecast for 2026-2028?

(NASDAQ: TKNO) Alpha Teknova's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 18.35%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.04%.

Alpha Teknova's earnings in 2026 is -$16,769,000.On average, 9 Wall Street analysts forecast TKNO's earnings for 2026 to be -$16,702,413, with the lowest TKNO earnings forecast at -$16,836,634, and the highest TKNO earnings forecast at -$16,348,071. On average, 9 Wall Street analysts forecast TKNO's earnings for 2027 to be -$14,511,933, with the lowest TKNO earnings forecast at -$15,258,200, and the highest TKNO earnings forecast at -$12,401,985.

In 2028, TKNO is forecast to generate -$10,587,322 in earnings, with the lowest earnings forecast at -$11,049,041 and the highest earnings forecast at -$10,147,078.

What is TKNO's revenue growth forecast for 2026-2028?

(NASDAQ: TKNO) Alpha Teknova's forecast annual revenue growth rate of 12.06% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 10.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.34%.

Alpha Teknova's revenue in 2026 is $43,700,000.On average, 9 Wall Street analysts forecast TKNO's revenue for 2026 to be $2,501,389,069, with the lowest TKNO revenue forecast at $2,304,514,271, and the highest TKNO revenue forecast at $2,604,416,813. On average, 9 Wall Street analysts forecast TKNO's revenue for 2027 to be $2,860,939,253, with the lowest TKNO revenue forecast at $2,681,352,070, and the highest TKNO revenue forecast at $2,999,025,422.

In 2028, TKNO is forecast to generate $3,325,557,334 in revenue, with the lowest revenue forecast at $3,072,685,695 and the highest revenue forecast at $3,523,291,144.

What is TKNO's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: TKNO) forecast ROA is N/A, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 23.57%.

What is TKNO's Price Target?

According to 2 Wall Street analysts that have issued a 1 year TKNO price target, the average TKNO price target is $7.50, with the highest TKNO stock price forecast at $8.00 and the lowest TKNO stock price forecast at $7.00.

On average, Wall Street analysts predict that Alpha Teknova's share price could reach $7.50 by Aug 11, 2027. The average Alpha Teknova stock price prediction forecasts a potential upside of 5.93% from the current TKNO share price of $7.08.

What is TKNO's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: TKNO) Alpha Teknova's current Earnings Per Share (EPS) is -$0.31. On average, analysts forecast that TKNO's EPS will be -$0.31 for 2026, with the lowest EPS forecast at -$0.31, and the highest EPS forecast at -$0.30. On average, analysts forecast that TKNO's EPS will be -$0.27 for 2027, with the lowest EPS forecast at -$0.28, and the highest EPS forecast at -$0.23. In 2028, TKNO's EPS is forecast to hit -$0.20 (min: -$0.21, max: -$0.19).

What is TKNO's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: TKNO) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.